3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
2
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
13
Neoplasms
9
Lung Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Disease
2
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Psychological Well-Being
1
Prostatic Neoplasms
1
Personal Satisfaction
1
Peripheral Nervous System Diseases
1
Pelvic Floor Disorders
1
Ovarian Neoplasms
1
Obesity
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Muscular Atrophy
1
Mesothelioma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Esophageal Neoplasms
1
Edema
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cardiotoxicity
1
Carcinoma, Non-Small-Cell Lung
1
Cancer Patients
1
Cachexia
1
Interventions
Gemcitabine
8
Cystectomy
6
Cisplatin
5
Mitomycin
3
toripalimab
2
tislelizumab
2
disitamab vedotin
2
Radiotherapy
2
Radiosurgery
2
Magnetic Resonance Spectroscopy
2
Drug Therapy
2
zimberelimab
1
trilaciclib
1
sacituzumab govitecan
1
nimotuzumab
1
entinostat
1
durvalumab
1
cemiplimab
1
Transurethral Resection of Bladder
1
Therapeutics
1
Synapsins
1
Saline Solution
1
Radiotherapy, Intensity-Modulated
1
RC48 antibody
1
Olive Oil
1
Niacinamide
1
Niacin
1
Music Therapy
1
Liquid Biopsy
1
Immunonutrition Diet
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Urinary Bladder Neoplasms
×
Exercise
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled